Market News & Trends
Mereo BioPharma & Oncologie Enter Global Licensing Agreement
Mereo BioPharma Group plc and Oncologie, Inc. recently announced a global license agreement for the development and commercialization of navicixizumab, an anti-DLL4/VEGF bispecific antibody currently…
OncoCyte Announces Agreement to Acquire Molecular Diagnostics Company
OncoCyte Corporation recently announced it has entered into an agreement to acquire, through a subsidiary, all of the outstanding capital stock of privately-held Insight Genetics,…
Innovative Micro-Infusion Pump From Gerresheimer Subsidiary Sensile Medical for EVER Pharma
Developed specially by Sensile Medical for EVER Pharma under the brand name D-mine, this wearable micro-infusion pump has already been launched in several European countries.…
CytoDyn Files for Breakthrough Therapy Designation With the FDA
CytoDyn Inc. recently announced it has filed for Breakthrough Therapy designation (BTD) with the US FDA for the use of leronlimab as an adjuvant therapy…
Adaptimmune Announces SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
Adaptimmune Therapeutics plc recently announced two confirmed Partial Responses (PRs) – one in a patient with liver cancer and one in a patient with melanoma. There…
Novavax Granted Fast-Track Designation
Novavax, Inc. recently announced the US FDA has granted Fast-Track Designation for NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate, adjuvanted with Matrix-M, in adults…
WPD Pharmaceuticals’ New Discovery for Cancer Targeting Drugs is Granted Patent
WPD Pharmaceuticals recently announced Wake Forest University received a patent from the United States Patent and Trademark Office (USPTO) for patent 105019210 (issued under application…
Oxford BioTherapeutics Initiates Dose-Escalation Portion of Phase I Clinical Trial
Oxford BioTherapeutics Ltd. recently announced the initiation of the dose-escalation portion of its US Phase 1 program for OBT076, a CD205 targeting antibody-drug conjugate (ADC),…
Zai Lab & Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial
Zai Lab Limited and Novocure recently announced the first patient has been enrolled in a Phase 2 pilot clinical trial evaluating the safety and efficacy…
TYME Announces First Patient Dosed in Pivotal Trial
Tyme Technologies, Inc. recently announced the first pancreatic cancer patient has been dosed in Part 2 of the TYME-88-Panc pivotal trial designed to support approval…